African Medicines Agency

The African Medicines Agency (AMA) is the African Union's continental regulatory body for medical products, established by the Treaty for the Establishment of the African Medicines Agency, which entered into force in November 2019 after reaching the threshold of ratifications. It is headquartered in Kigali, Rwanda. The AMA's mandate is to harmonise medicines regulation across African Union member states, facilitate mutual recognition of regulatory decisions, support regional access to quality-assured medical products, and coordinate regulatory responses during health emergencies.

For the Bundibugyo PHEIC, the AMA was named by Africa CDC as one of the partners on its 16 May 2026 coordination call. Its role in an outbreak response context relates to the regulatory architecture for any emergency use authorisation of experimental or off-label medical countermeasures — precisely the regulatory question that the absence of any licensed Bundibugyo vaccine or therapeutic raises. If Regeneron's REGN3479 component or any other candidate were to be considered for compassionate use, the AMA would be the regulatory body through which African-market access would be coordinated.

The AMA represents the African Union's shift toward regulatory sovereignty — reducing dependence on EMA, FDA, or WHO prequalification as the sole gatekeepers for medicines available in Africa. Its establishment was a post-COVID priority, and its involvement in the Bundibugyo coordination call signals that Africa's continental regulatory architecture is being treated as a primary partner in the response, not an afterthought. The practical limitation is that the AMA is still building its operational capacity; its ability to accelerate compassionate-use regulatory approvals in weeks rather than months is as yet untested at PHEIC scale.